Multiple sclerosis is a chronic and often disabling disease of the nervous system, affecting about 1 million people worldwide. Even though it has been known for over a hundred years, no cause or cure has yet been discovered—but now there is hope. New therapies have been shown to slow the disease progress in some patients, and the pace of discoveries about the cellular machinery of the brain and spinal cord has accelerated.
This book presents a comprehensive overview of multiple sclerosis today, as researchers seek to understand its processes, develop therapies that will slow or halt the disease and perhaps repair damage, offer relief for specific symptoms, and improve the abilities of MS patients to function in their daily lives.
The panel reviews existing knowledge and identifies key research questions, focusing on:
The committee also discusses ways to build and financially support the MS research enterprise, including a look at challenges inherent in designing clinical trials. This book will be important to MS researchers, research funders, health care advocates for MS research and treatment, and interested patients and their families.
Table of Contents |
skim chapter | |
|---|---|---|
| Front Matter | i-xviii | |
| Executive Summary | 1-16 | |
| 1 Introduction | 17-28 | |
| 2 Clinical and Biological Features | 29-114 | |
| 3 Characteristics and Management of Major Symptoms | 115-176 | |
| 4 Disease Management and Measurement | 177-240 | |
| 5 Strategies for Future Research on Disease Mechanisms | 241-276 | |
| 6 Future Strategies for Therapies | 277-324 | |
| 7 Building and Supporting the Research Enterprise | 325-346 | |
| 8 Recommendations | 347-368 | |
| Appendix A: Committee and Staff Biographies | 369-376 | |
| Appendix B: List of Expert Consultants | 377-378 | |
| Appendix C: Workshop Agendas | 379-384 | |
| Appendix D: Kurtze's Expanded Disability Status Scale | 385-386 | |
| Appendix E: Drugs Used in the Treatment of MS | 387-400 | |
| Appendix F: U.S. Social Security Administration's Criteria for Qualifying as Disabled from MS | 401-404 | |
| Appendix G: Treatments That Have Been Claimed to Be of Benefit in MS | 405-412 | |
| Index | 413-438 | |
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
E-mail: info@copyright.com
Web: https://www.copyright.com
Loading stats for Multiple Sclerosis: Current Status and Strategies for the Future...
Finding similar items...
